DATE: Thursday, May 15, 2025
TIME:
- 8:00 am PT (Pacific Time – North America)
- 11:00 am ET (Eastern Time – North America)
- 5:00 pm CET (Central European Time)
In this webinar, Dr. Brady Wu will discuss bispecific antibody drugs and their production.
First, he will provide a comprehensive overview of the history and development of bispecific antibodies (BsAbs), including their structural biology and strategies like the “common light chain (cLC) approach” to resolve chain mispairing issues. Next, he will elaborate on the mechanisms of action of BsAb drugs and challenges in selecting the most active bispecific candidates: currently, over 100 BsAb structural formats exist, with most designed using “knobs-into-holes (KIH)” engineering principles.
Regarding BsAb production, Dr. Wu will highlight Biointron’s expertise in molecular formats like KIH, IgG-scFv, and IgG-VHH, and present solutions for addressing molecular mispairing and impurity removal during manufacturing. Additionally, he will share case studies and strategies to enhance antibody expression levels and optimize purification processes to meet diverse client requirements.
Finally, Dr. Wu will introduce his company’s infrastructure, R&D advantages in bispecific/multispecific antibody fields, and service features. This will include discussions on platform technologies for accelerating therapeutic development and customized solutions for complex antibody engineering challenges.
Key Topics Include:
- Explore the journey of bispecific antibodies from their 1980s origins to cutting-edge products and platforms
- Discuss breakthroughs in the therapeutic area including oncology/immunotherapy
- Analyze the key hurdles in production: structural complexity, stability, and scalable production